Landos Biopharma, Inc. (LABP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Landos Biopharma, Inc. (LABP) trades at $22.93. Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for autoimmune diseases. Market cap: 72M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for LABP: LABP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LABP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LABP: 1/1 perspectives are bearish.
Landos Biopharma, Inc. (LABP) Healthcare & Pipeline Overview
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in oral therapeutics for autoimmune diseases, with a focus on gut-restricted and systemically bioavailable small molecules. Their lead candidate, omilancor, targets LANCL2 for the treatment of ulcerative colitis, Crohn's disease, and eosinophilic esophagitis, positioning them in a competitive biotechnology landscape.
What Is the Investment Thesis for LABP?
Landos Biopharma, Inc. presents a compelling investment thesis centered on its innovative pipeline of oral therapeutics targeting autoimmune diseases. The company's lead candidate, omilancor, has the potential to address a significant market in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis. A successful clinical trial outcome for omilancor could drive substantial value. The company's market capitalization is approximately $0.07 billion as of 2026-03-16. Key risks include clinical trial failures and competition from established pharmaceutical companies. The company's P/E ratio is -6.56, reflecting its current lack of profitability. Positive clinical data and strategic partnerships could serve as major catalysts for growth.
Based on FMP financials and quantitative analysis
LABP Key Highlights
- Market capitalization of $0.07 billion indicates the company's current valuation in the market.
- P/E ratio of -6.56 reflects the company's current lack of profitability due to ongoing research and development expenses.
- Lead product candidate, omilancor, targets a significant market in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.
- The company's pipeline includes multiple preclinical candidates targeting a range of autoimmune diseases.
- Beta of 0.14 suggests lower volatility compared to the overall market.
Who Are LABP's Competitors?
LABP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACHL Achilles Therapeutics plc | $1.48 | +0.68% | $60.83M | 47 |
| BLI Berkeley Lights, Inc. | $1.20 | -5.88% | $86.61M | 51 |
| HTBX Heat Biologics, Inc. | $2.38 | +0.42% | $61.07M | 48 |
| IGMS IGM Biosciences, Inc. | $1.27 | +0.00% | $77.50M | 60 |
| JBIO Jade Biosciences, Inc. | $15.94 | -0.87% | 521M | 50 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LABP's Key Strengths?
- Novel oral therapeutics for autoimmune diseases
- Targeting specific pathways like LANCL2 and NOD-like receptor X1
- Strong intellectual property portfolio
- Experienced management team
What Are LABP's Weaknesses?
- Clinical-stage company with no approved products
- High research and development costs
- Reliance on successful clinical trial outcomes
- Limited financial resources
What Could Drive LABP Stock Higher?
- Data readout from ongoing clinical trials of omilancor in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.
- Initiation of clinical trials for LABP-104 in systemic lupus erythematosus and rheumatoid arthritis.
- Progress in preclinical development of LABP-66, LABP-69, LABP-73, and LABP-111.
- Potential for strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for LABP?
- Clinical trial failures for omilancor or other product candidates.
- Competition from established pharmaceutical companies with approved autoimmune disease therapies.
- Regulatory delays or rejection of product candidates.
- Patent expirations and intellectual property challenges.
- High research and development costs.
What Are the Growth Opportunities for LABP?
- Omilancor's Clinical Development: The successful advancement of omilancor through clinical trials represents a significant growth opportunity for Landos Biopharma. Positive Phase 3 data in ulcerative colitis, Crohn's disease, or eosinophilic esophagitis could lead to regulatory approval and commercialization. The market for these indications is substantial, with ulcerative colitis alone projected to reach billions of dollars. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
- Expansion of Pipeline: Landos Biopharma's preclinical pipeline offers several growth opportunities. The development of LABP-104 for systemic lupus erythematosus and rheumatoid arthritis could expand the company's reach into additional autoimmune indications. Similarly, LABP-66, LABP-69, LABP-73, and LABP-111 target other diseases, including multiple sclerosis, Alzheimer's disease, diabetic nephropathy, asthma, chronic obstructive pulmonary disease, nonalcoholic steatohepatitis and type 1 diabetes. Timeline: Preclinical development ongoing with potential clinical trials in the next 2-3 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Landos Biopharma's product candidates. These partnerships could provide funding, expertise, and access to broader markets. Collaborations could also involve licensing agreements or joint development programs. Timeline: Ongoing discussions with potential partnerships in the next 1-2 years.
- Targeting LANCL2 Pathway: Landos Biopharma's focus on the LANCL2 pathway represents a unique growth opportunity. LANCL2 is a novel target with potential applications in multiple autoimmune diseases. Further research into the LANCL2 pathway could lead to the discovery of additional therapeutic candidates. Timeline: Ongoing research with potential for new discoveries in the next 3-5 years.
- Oral Therapeutics Market: The increasing preference for oral therapeutics over injectable or infused therapies creates a favorable environment for Landos Biopharma's oral drug candidates. Oral drugs offer convenience and ease of administration, which can improve patient compliance and outcomes. The market for oral autoimmune disease therapies is expected to grow significantly in the coming years. Timeline: Ongoing trend with increasing adoption of oral therapies.
What Opportunities Does LABP Have?
- Successful clinical development of omilancor
- Expansion of pipeline into additional autoimmune indications
- Strategic partnerships with larger pharmaceutical companies
- Growing market for oral autoimmune disease therapies
What Threats Does LABP Face?
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
What Are LABP's Competitive Advantages?
- Proprietary oral drug formulations
- Targeting novel pathways like LANCL2 and NOD-like receptor X1
- Strong intellectual property portfolio
- Experienced management team
What Does LABP Do?
Landos Biopharma, Inc., founded in 2017 and headquartered in Blacksburg, Virginia, is a biopharmaceutical company dedicated to discovering and developing innovative oral therapeutics for patients suffering from autoimmune diseases. The company's core strategy revolves around targeting specific pathways within the body to modulate the immune system and alleviate the symptoms associated with these chronic conditions. Landos Biopharma's lead product candidate, omilancor, is a gut-restricted oral therapeutic that targets lanthionine synthetase C-like protein 2 (LANCL2). Omilancor is currently in development for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. In addition to omilancor, Landos Biopharma is also developing NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD. Furthermore, LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA), is also in their pipeline. The company's preclinical pipeline includes LABP-66 for multiple sclerosis and Alzheimer's disease, LABP-69 for diabetic nephropathy and RA, LABP-73 for asthma and chronic obstructive pulmonary disease, and LABP-111 for nonalcoholic steatohepatitis and type 1 diabetes. Landos Biopharma aims to provide convenient and effective oral therapies for patients with autoimmune diseases, addressing significant unmet medical needs.
What Products and Services Does LABP Offer?
- Develop oral therapeutics for autoimmune diseases
- Target lanthionine synthetase C-like protein 2 (LANCL2)
- Develop treatments for ulcerative colitis (UC)
- Develop treatments for Crohn's disease (CD)
- Develop treatments for eosinophilic esophagitis
- Develop treatments for systemic lupus erythematosus and rheumatoid arthritis (RA)
- Develop treatments for multiple sclerosis and Alzheimer's disease
- Develop treatments for diabetic nephropathy, asthma, chronic obstructive pulmonary disease, nonalcoholic steatohepatitis and type 1 diabetes
How Does LABP Make Money?
- Discover and develop novel oral therapeutics
- Conduct preclinical and clinical trials
- Seek regulatory approval for product candidates
- Commercialize approved products or partner with larger pharmaceutical companies
What Industry Does LABP Operate In?
Landos Biopharma operates within the competitive biotechnology industry, focusing on autoimmune disease therapeutics. The market for autoimmune disease treatments is substantial and growing, driven by an increasing prevalence of these conditions and advancements in understanding their underlying mechanisms. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies. Landos Biopharma differentiates itself through its focus on oral therapeutics and specific targets like LANCL2 and NOD-like receptor X1. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant returns on successful products.
Who Are LABP's Key Customers?
- Patients with autoimmune diseases
- Healthcare providers
- Pharmaceutical companies (potential partners)
LABP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in LABP's future, indicating that key stakeholders see potential upside.
- Community sentiment has shifted positively with increasing discussions around LABP's innovative treatments, reflecting growing enthusiasm.
- Recent partnerships and collaborations in the biotech sector have positioned LABP favorably among peers, enhancing its credibility.
- Upcoming clinical trial results are anticipated, which could catalyze interest and investment if outcomes are promising.
Bear Case
- Market perception remains cautious due to the inherent risks associated with biotech stocks, particularly those in early-stage development.
- Negative sentiment has emerged from recent delays in regulatory approvals, causing concern among investors about LABP's timeline.
- Some analysts express skepticism over the scalability of LABP's technologies, raising doubts about long-term profitability.
- Community discussions have highlighted a lack of clear communication from management, leading to uncertainty and mistrust among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LABP Latest News
No recent news available for LABP.
LABP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LABP.
Price Targets
Wall Street price target analysis for LABP.
LABP MoonshotScore
What does this score mean?
The MoonshotScore rates LABP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gregory Oakes
CEO
Gregory Oakes serves as the CEO of Landos Biopharma, bringing extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, where he focused on drug development, commercialization, and strategic partnerships. He has a proven track record of building and managing successful teams. Oakes is responsible for overseeing Landos Biopharma's overall strategy, operations, and financial performance.
Track Record: Under Gregory Oakes' leadership, Landos Biopharma has advanced its lead product candidate, omilancor, through clinical trials. He has also overseen the expansion of the company's pipeline and the formation of strategic partnerships. His focus has been on driving innovation and creating value for shareholders.
What Investors Ask About Landos Biopharma, Inc. (LABP) — Healthcare
What does Landos Biopharma, Inc. do?
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral therapeutics for autoimmune diseases. Their lead product candidate, omilancor, is a gut-restricted oral therapeutic targeting lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis, Crohn's disease, and eosinophilic esophagitis. The company also has a pipeline of preclinical candidates targeting other autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and Alzheimer's disease. Landos Biopharma aims to provide convenient and effective oral therapies for patients with autoimmune conditions.
What are the main risks for LABP?
The main risks for Landos Biopharma, Inc. include the inherent uncertainties of clinical drug development. Clinical trial failures or delays could significantly impact the company's value. Competition from established pharmaceutical companies with approved autoimmune disease therapies also poses a risk. Regulatory hurdles and potential patent expirations could also affect the company's prospects. Additionally, the company's reliance on external funding and strategic partnerships exposes it to financial and operational risks.
What are the key factors to evaluate for LABP?
Evaluate LABP on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does LABP data refresh on this page?
LABP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LABP's recent stock price performance?
Landos Biopharma, Inc. (LABP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel oral therapeutics for autoimmune diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LABP overvalued or undervalued right now?
Valuing Landos Biopharma, Inc. (LABP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LABP?
Before investing in Landos Biopharma, Inc. (LABP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LABP to a portfolio?
Key strength of Landos Biopharma, Inc. (LABP): Novel oral therapeutics for autoimmune diseases. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending for LABP.